X4 Pharmaceuticals (XFOR) Depreciation and Depletion (2023 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Depreciation and Depletion came in at $168000.0 in Q2 2025, up 143.48% YoY from $69000.0 in Q2 2024, and down 41.87% on a QoQ basis from $289000.0 in Q1 2025.
X4 Pharmaceuticals (XFOR) Depreciation and Depletion (2023 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 3 years of Depreciation and Depletion data on file, last reported at $168000.0 in Q2 2025.
- Quarterly Depreciation and Depletion rose 143.48% year-over-year to $168000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $626000.0 (up 125.18% YoY) and the FY2025 annual result came in at $500000.0, up 66.67% from the prior year.
- Depreciation and Depletion slipped to $168000.0 in Q2 2025, from $289000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $289000.0 in Q1 2025 to a low of $43000.0 in Q4 2023.
- A 3-year average of $113000.0 and a median of $84500.0 in 2024 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2024 — Depreciation and Depletion slipped 23.08% — and 2025, when it jumped 366.13%.
- Tracing XFOR's Depreciation and Depletion over 3 years: stood at $43000.0 in 2023, then soared by 106.98% to $89000.0 in 2024, then soared by 88.76% to $168000.0 in 2025.
- The last three Depreciation and Depletion figures came in at $168000.0 (Q2 2025), $289000.0 (Q1 2025), and $89000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 168,000.00 |
| Jun 30, 2025 | 168,000.00 |
| Mar 31, 2025 | 289,000.00 |
| Mar 31, 2025 | 289,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Sep 30, 2023 | 104,000.00 |
| Sep 30, 2023 | 104,000.00 |